Janus Kinase Inhibitor

Drug maker Gilead Sciences has announced it will no longer pursue FDA approval for its janus kinase inhibitor filgotinib in the treatment of rheumatoid arthritis, according to a company press release.

The combination of everolimus and itacitinib, an oral JAK inhibitor, was well-tolerated in patients with relapsed or refractory Hodgkin lymphoma, according to data presented at ASH Annual Meeting and Exposition.

The emergence of novel therapies over the last decade has turned the treatment of rheumatoid arthritis upside down.

In this video, Dana DiRenzo, MD, MHS, instructor of medicine at Johns Hopkins, summarized “The Great Debate” at ACR 2020

The ACR’s annual Great Debate featured spirited arguments made for and against the use of janus kinase inhibitors before biologic therapy in the setting of methotrexate failure in rheumatoid arthritis.

A gut-selective Janis kinase inhibitor called TD-1473 showed a trend toward reduced ulcerative colitis disease activity in a translational medicine program.

Ruxolitinib induced responses in about one-third of a cohort of patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia, according to results of a single-arm phase 2 study published in Journal of Clinical Oncology.

Upadacitinib reduced all clinical disease measures including itch-related outcomes at 16 weeks in patients with moderate to severe atopic dermatitis, according to phase 2b study results published in Journal of Allergy and Clinical Immunology.

SAN ANTONIO — A post hoc analysis evaluating the safety of Xeljanz in ulcerative colitis revealed comparable incidence rates of pulmonary embolism and deep vein thrombosis in patients who did and did not receive the agent. However, researchers at the American College of Gastroenterology Annual Meeting stressed the need for more data to better understand the link between the agent and venous thromboembolic events after previous safety signals led to a change in prescribing guidelines in the United States.

In the top story from last week, Deanne Mraz Robinson, MD, describes how at-home therapy, such as LED light therapy along with in-office platelet-rich plasma injections, helps to prevent further hair loss and protect the hair growth already achieved.